8-K: Kairos Pharma Engages Cross Current Capital for Strategic Consulting Services

Kairos Pharma has entered into a consulting agreement with Cross Current Capital for financial and business advisory services, including a cash payment of $200,000 and $500,000 in restricted stock.

Summary

• Kairos Pharma, a clinical-stage biopharmaceutical company, has engaged Cross Current Capital for strategic business and financial consulting.
• The consulting agreement includes services such as drafting a competitive overview, valuation analysis, marketing materials, and investor relations.
• Kairos Pharma will pay Cross Current $200,000 in cash and issue $500,000 worth of restricted shares to the advisor, Alan Masley.
• The shares will vest after six months, with a potential true-up or return of shares to maintain the $500,000 valuation.
• The consulting agreement is for an initial term of 24 months, with a possible 12-month extension.
• Cross Current will also be reimbursed for pre-approved expenses.

Sentiment

Score: 7

Explanation: The document indicates a positive step for Kairos Pharma in securing strategic advice, but the issuance of stock and potential dilution temper the overall sentiment.

Positives

• Kairos Pharma is engaging experienced consultants to assist with strategic business and financial planning.
• The consulting agreement covers a wide range of services, including investor relations and capital markets advisory.
• The agreement includes a mechanism to ensure the advisor receives the full $500,000 value in shares, either through a true-up or return of shares.
• The agreement has a defined term of 24 months with an option to extend, providing stability and continuity.

Negatives

• The company is issuing a significant amount of stock to pay for consulting services, which could dilute existing shareholders.
• The vesting period of six months for the shares means the advisor may not be fully aligned with the long-term interests of the company until after this period.
• The agreement includes a clause that the advisor will not receive more than 9.99% of the company's issued and outstanding common stock, which could limit the advisor's potential upside.

Risks

• The success of the consulting engagement depends on the effectiveness of Cross Current's advice and execution.
• The issuance of restricted shares could lead to dilution of existing shareholders.
• There is a risk that the company may not be able to achieve its business objectives despite the consulting services.
• The agreement is subject to the laws of the State of New York, which may introduce legal risks.

Future Outlook

The consulting agreement is expected to provide strategic business and financial advice to Kairos Pharma over the next 24 months, with a potential 12-month extension. The company intends to file a registration statement on Form S-8 within 30 days of completing after entry into this Agreement.

Management Comments

• John S. Yu, Chief Executive Officer of Kairos Pharma, signed the 8-K report on behalf of the company.

Industry Context

This agreement is typical for a clinical-stage biopharmaceutical company seeking to advance its business strategy and secure funding. Engaging financial and business consultants is a common practice to support growth and development.

Comparison to Industry Standards

• The use of a combination of cash and equity for consulting services is a common practice in the biotech industry, particularly for early-stage companies.
• The vesting period of six months for the restricted shares is relatively standard, aligning the consultant's interests with the company's short-term performance.
• The scope of services outlined in the agreement is comprehensive, covering various aspects of business and financial strategy, which is typical for a company seeking to grow and attract investment.
• Comparable companies often engage consultants for similar services, such as preparing for capital raises, investor relations, and strategic planning. For example, companies like Xencor and Arcus Biosciences have used consultants for similar purposes.

Stakeholder Impact

• Shareholders may experience dilution due to the issuance of restricted shares.
• Employees may benefit from the strategic guidance provided by the consultants.
• The company's ability to attract investors may be enhanced by the consulting services.
• Creditors may be impacted by the company's financial performance and ability to repay debts.

Next Steps

• Cross Current Capital will begin providing consulting services to Kairos Pharma.
• Kairos Pharma will issue the cash payment and restricted shares to Cross Current and Alan Masley.
• Kairos Pharma intends to file a registration statement on Form S-8 within 30 days of completing after entry into this Agreement.

Key Dates

Keywords

consulting agreement, financial advisory, business consulting, restricted stock, investor relations, capital markets, valuation analysis, biopharmaceutical, strategic planning, M&A